Date: 16 February 2017
Craigavon, N.I., 16 February 2017
Almac Diagnostics, the global personalised medicine company, focusing on the discovery, development and commercialisation of complex diagnostic and companion diagnostic tests, has announced the appointment of Dr. Leeona Galligan (PhD, FRCPath) to the position of Vice President, UK Operations.
In her new role, Dr Galligan will be responsible for all UK based operations including commercial biomarker discovery, CLIA/FDA compliant analytical validation, downstream clinical testing, manufacturing and shipping of clinical specimen and release of controls and reagents for registrational clinical trials. In addition, she will continue to serve as a valuable member of the Almac Diagnostics’ Executive team helping to define and implement its global business strategy.
Leeona joined Almac Diagnostics in September 2009 as a Senior Scientist within its research and development department. In 2012, she was appointed Manager of the newly formed clinical testing laboratory and, in 2014, was subsequently promoted to Head of UK laboratory based Operations.
Leeona obtained a B.Sc (Hons) in Genetics and a M.Med.Sc. (Laboratory Science) from Queen’s University Belfast and received her PhD in molecular haematology from Trinity College Dublin in 2003. Her research focused on the isolation and characterisation of a novel cellular receptor that is targeted in the treatment of sepsis. She subsequently completed a postdoctoral fellowship on the molecular mechanisms of drug resistance in colorectal cancer at the Department of Oncology at Queen’s University Belfast.
Following her Postdoctoral Fellowship, Leeona completed a 4 year training programme in specialist haemato-oncology laboratory services leading to her registration with the UK Health and Care Professions Council as a Clinical Scientist. She has also been awarded Fellowship of the Royal College of Pathologists (FRCPath) through examination in haemato-oncology and laboratory management.
“Leeona’s appointment to VP UK Operations is in recognition of the significant contribution she has made to our business over the past eight years,” said Paul Harkin, Managing Director & President, Almac Diagnostics.
“Her wealth of experience and expertise in the personalised medicine arena is a valuable asset which will help strengthen and deepen our Management team. We look forward to working together to further develop our strategy and continue to offer our global clients an expanded array of services.”
Notes to editors
About Almac Diagnostics
Almac Diagnostics is a global personalised medicine company, focusing on the discovery, development and commercialisation of complex diagnostic and companion diagnostic tests.
Our global, state of the art, CLIA-accredited labs in the USA and Europe are ready to operate both research-use-only and clinical diagnostic assays. Our flexible approach allows Almac Diagnostics to be platform agile and to provide genuinely novel Diagnostic and CDx solutions for even the most challenging of Pharma and BioTech clients.
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).